Key Drivers
- Strong Liquidity Position
- Tax-Boosted Earnings
- Declining Debt Balance
AIAI Summary
Aurinia's Teva settlement transforms AUPH into a cash-generative, single-product specialty-pharma franchise with U.S. LUPKYNIS exclusivity through 2036, but investors should require confirmation of sustainable revenue growth and normalized free cash flow before underwriting a rerating given persistent concentration risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity Position
- •Tax-Boosted Earnings
- •Declining Debt Balance
AUPH has strong profitability and liquidity, but tax-boosted earnings inflate valuation metrics, warranting caution despite a seemingly low P/E.
Price Behavior
Key Price Behavior Insights:
- •Recent rebound
- •Momentum paused
- •Breakout needed
AUPH is cautiously constructive after rebounding from $16.05 and holding above its last-month average, but it needs a sustained break above $17.27 to confirm a stronger uptrend.
Sharp jump from $16.13 to $16.96 on 2026-09-16
Sentiment & News
Key News Insights:
- •Generic Delay
- •Patent Settlement
- •Share Upside
Aurinia's Teva settlement delays U.S. voclosporin generics until December 2036, supporting AUPH's revenue visibility and premarket share gains.
The agreement materially strengthens AUPH's long-term competitive protection in the U.S
Similar Companies in Healthcare
Other companies in the same sector with AI ratings